This program was made doable with help from Novartis Prescribed drugs.
Video content material above is prompted by the next questions:
- As a affected person advocate, how do you assist newly recognized CML sufferers and their caregivers navigate the complexities of the analysis and set acceptable care objectives? What are a number of the largest challenges sufferers could face at this stage?
- What assets or academic supplies have you ever discovered most useful in supporting newly recognized CML sufferers and their caregivers?
- How do sufferers sometimes use these supplies? How have you ever modified your approaches so sufferers and caregivers can greatest leverage these supplies?
